SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...
Edwards Lifesciences gains attention after fresh valve data as structural heart devices, valuation debate, and healthcare sentiment remain in focus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results